EP2968489B1 - Her2/neu-krebsimpfstoff - Google Patents
Her2/neu-krebsimpfstoff Download PDFInfo
- Publication number
- EP2968489B1 EP2968489B1 EP14712205.5A EP14712205A EP2968489B1 EP 2968489 B1 EP2968489 B1 EP 2968489B1 EP 14712205 A EP14712205 A EP 14712205A EP 2968489 B1 EP2968489 B1 EP 2968489B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino acid
- protein
- sequence
- her2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150029707 ERBB2 gene Proteins 0.000 title claims description 45
- 229940022399 cancer vaccine Drugs 0.000 title claims description 40
- 238000009566 cancer vaccine Methods 0.000 title description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 142
- 150000001413 amino acids Chemical class 0.000 claims description 120
- 102000004169 proteins and genes Human genes 0.000 claims description 119
- 108091007433 antigens Proteins 0.000 claims description 105
- 102000036639 antigens Human genes 0.000 claims description 105
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 79
- 230000003612 virological effect Effects 0.000 claims description 65
- 239000002245 particle Substances 0.000 claims description 59
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 55
- 125000000539 amino acid group Chemical group 0.000 claims description 51
- 230000002163 immunogen Effects 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 32
- 238000000746 purification Methods 0.000 claims description 24
- 230000028993 immune response Effects 0.000 claims description 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
- 238000007792 addition Methods 0.000 claims description 20
- 108010044241 tetanus toxin fragment C Proteins 0.000 claims description 17
- 230000037430 deletion Effects 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 238000004132 cross linking Methods 0.000 claims description 11
- 239000003431 cross linking reagent Substances 0.000 claims description 11
- 238000010382 chemical cross-linking Methods 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 9
- ZACLXWTWERGCLX-MDUHGFIHSA-N dom-1 Chemical group O([C@@H]1C=C(C([C@@H](O)[C@@]11CO)=O)C)[C@@H]2[C@H](O)C[C@@]1(C)C2=C ZACLXWTWERGCLX-MDUHGFIHSA-N 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000568 immunological adjuvant Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 235000018102 proteins Nutrition 0.000 description 104
- 241000196324 Embryophyta Species 0.000 description 80
- 229960005486 vaccine Drugs 0.000 description 68
- 241000894007 species Species 0.000 description 60
- 241000282414 Homo sapiens Species 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 49
- 241000723873 Tobacco mosaic virus Species 0.000 description 45
- 235000001014 amino acid Nutrition 0.000 description 41
- 241000700159 Rattus Species 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 38
- 241000700605 Viruses Species 0.000 description 33
- 239000012634 fragment Substances 0.000 description 32
- 101710132601 Capsid protein Proteins 0.000 description 29
- 101710094648 Coat protein Proteins 0.000 description 29
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 29
- 101710125418 Major capsid protein Proteins 0.000 description 29
- 101710141454 Nucleoprotein Proteins 0.000 description 29
- 101710083689 Probable capsid protein Proteins 0.000 description 29
- 238000010367 cloning Methods 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 102000051957 human ERBB2 Human genes 0.000 description 22
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 18
- 239000002671 adjuvant Substances 0.000 description 17
- 230000017730 intein-mediated protein splicing Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 239000013604 expression vector Substances 0.000 description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 description 15
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 239000013603 viral vector Substances 0.000 description 13
- 108010078791 Carrier Proteins Proteins 0.000 description 12
- 102000014914 Carrier Proteins Human genes 0.000 description 12
- 240000007594 Oryza sativa Species 0.000 description 12
- 235000007164 Oryza sativa Nutrition 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 108090000565 Capsid Proteins Proteins 0.000 description 10
- 108010041986 DNA Vaccines Proteins 0.000 description 10
- 229940021995 DNA vaccine Drugs 0.000 description 10
- 108010055044 Tetanus Toxin Proteins 0.000 description 10
- 108090000637 alpha-Amylases Proteins 0.000 description 10
- 102000004139 alpha-Amylases Human genes 0.000 description 10
- 229940024171 alpha-amylase Drugs 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 235000009566 rice Nutrition 0.000 description 10
- 229940118376 tetanus toxin Drugs 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000005754 cellular signaling Effects 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108050006628 Viral movement proteins Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229940031670 conjugate vaccine Drugs 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000012552 review Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108010060123 Conjugate Vaccines Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 108060004795 Methyltransferase Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000723848 Tobamovirus Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 241001493065 dsRNA viruses Species 0.000 description 7
- 229940022353 herceptin Drugs 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229960000575 trastuzumab Drugs 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 206010043376 Tetanus Diseases 0.000 description 6
- 241001147459 Turnip vein-clearing virus Species 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 206010055113 Breast cancer metastatic Diseases 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000709992 Potato virus X Species 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 229940037003 alum Drugs 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000287 crude extract Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 108700020302 erbB-2 Genes Proteins 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229940023041 peptide vaccine Drugs 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 101100279566 Arabidopsis thaliana EMB514 gene Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101150054472 HER2 gene Proteins 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 101100268514 Mus musculus Serpina1a gene Proteins 0.000 description 4
- 241000207746 Nicotiana benthamiana Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 231100000319 bleeding Toxicity 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- -1 for example Substances 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000114864 ssRNA viruses Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 3
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 241000723762 Potato virus Y Species 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000006229 amino acid addition Effects 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229940023143 protein vaccine Drugs 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 108010020183 3-phosphoshikimate 1-carboxyvinyltransferase Proteins 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 241000724328 Alfalfa mosaic virus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000702451 Begomovirus Species 0.000 description 2
- 241000724256 Brome mosaic virus Species 0.000 description 2
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 2
- 101100054773 Caenorhabditis elegans act-2 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 241000702461 Curtovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241000702459 Mastrevirus Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000187481 Mycobacterium phlei Species 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241001533393 Potyviridae Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 2
- 241000961587 Secoviridae Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 241000192581 Synechocystis sp. Species 0.000 description 2
- 101000933110 Turnip vein-clearing virus Capsid protein Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000277 virosome Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Chemical class CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Chemical class CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Chemical class CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010000700 Acetolactate synthase Proteins 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000724330 Alfamovirus Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000405760 Alphapartitivirus Species 0.000 description 1
- 241000710009 Apple chlorotic leaf spot virus Species 0.000 description 1
- 241001135987 Apple stem grooving virus Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000701513 Badnavirus Species 0.000 description 1
- 241000725138 Banana bunchy top virus Species 0.000 description 1
- 241000724306 Barley stripe mosaic virus Species 0.000 description 1
- 241000709756 Barley yellow dwarf virus Species 0.000 description 1
- 241000724681 Barley yellow mosaic virus Species 0.000 description 1
- 241000702286 Bean golden mosaic virus Species 0.000 description 1
- 241000702325 Beet curly top virus Species 0.000 description 1
- 241000710149 Beet yellows virus Species 0.000 description 1
- 241000405758 Betapartitivirus Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 241000372028 Broad bean wilt virus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241001533462 Bromoviridae Species 0.000 description 1
- 241000724268 Bromovirus Species 0.000 description 1
- 241001533357 Bymovirus Species 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000710011 Capillovirus Species 0.000 description 1
- 241000710175 Carlavirus Species 0.000 description 1
- 241000714207 Carmovirus Species 0.000 description 1
- 241000710173 Carnation latent virus Species 0.000 description 1
- 241000714206 Carnation mottle virus Species 0.000 description 1
- 241000723666 Carnation ringspot virus Species 0.000 description 1
- 241000969784 Carrot mottle virus Species 0.000 description 1
- 241001515826 Cassava vein mosaic virus Species 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241001115395 Caulimoviridae Species 0.000 description 1
- 241000701459 Caulimovirus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000973027 Closteroviridae Species 0.000 description 1
- 241000710151 Closterovirus Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000724711 Coconut foliar decay virus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000723607 Comovirus Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000723655 Cowpea mosaic virus Species 0.000 description 1
- 241000948358 Crinivirus Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 241000975725 Cucumber vein yellowing virus Species 0.000 description 1
- 241000724253 Cucumovirus Species 0.000 description 1
- 241000712467 Cytorhabdovirus Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000723672 Dianthovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000723747 Enamovirus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000723648 Fabavirus Species 0.000 description 1
- 241001302129 Fiji disease virus Species 0.000 description 1
- 241000702658 Fijivirus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000723722 Furovirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241001478515 Grapevine fleck virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 241000384508 Hoplostethus atlanticus Species 0.000 description 1
- 241000724309 Hordeivirus Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241001533403 Idaeovirus Species 0.000 description 1
- 241000724277 Ilarvirus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001429356 Lettuce infectious yellows virus Species 0.000 description 1
- 241000191478 Lettuce necrotic yellows cytorhabdovirus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 108700027766 Listeria monocytogenes hlyA Proteins 0.000 description 1
- 241000709757 Luteovirus Species 0.000 description 1
- 241001533339 Machlomovirus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 1
- 241000611254 Maize rayado fino virus Species 0.000 description 1
- 241000702489 Maize streak virus Species 0.000 description 1
- 241000442455 Maize white line mosaic virus Species 0.000 description 1
- 241000709759 Marafivirus Species 0.000 description 1
- 241000711513 Mononegavirales Species 0.000 description 1
- 241000187488 Mycobacterium sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000723638 Nepovirus Species 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 241000712466 Nucleorhabdovirus Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Chemical class CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001467023 Olive latent virus 2 Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 241000712894 Orthotospovirus Species 0.000 description 1
- 241000702633 Oryzavirus Species 0.000 description 1
- 241001112513 Ourmia melon virus Species 0.000 description 1
- 101710160102 Outer membrane protein B Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000726026 Parsnip yellow fleck virus Species 0.000 description 1
- 241000710936 Partitiviridae Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241001443531 Pea enation mosaic virus 1 Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000220691 Pelargonium zonate spot virus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000609851 Petunia vein clearing virus Species 0.000 description 1
- 241001112770 Petuvirus Species 0.000 description 1
- 241000702656 Phytoreovirus Species 0.000 description 1
- 108020005089 Plant RNA Proteins 0.000 description 1
- 241000269980 Pleuronectidae Species 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001474398 Potato yellow dwarf nucleorhabdovirus Species 0.000 description 1
- 241000710007 Potexvirus Species 0.000 description 1
- 241000710078 Potyvirus Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000724648 Raspberry bushy dwarf virus Species 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 241000700161 Rattus rattus Species 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000144068 Rice ragged stunt virus Species 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 241000701507 Rice tungro bacilliform virus Species 0.000 description 1
- 241001492231 Rice tungro spherical virus Species 0.000 description 1
- 241000124072 Ryegrass mosaic virus Species 0.000 description 1
- 241001533356 Rymovirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000709666 Sequivirus Species 0.000 description 1
- 241000710119 Sobemovirus Species 0.000 description 1
- 241001135883 Soil-borne wheat mosaic virus Species 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 241000710117 Southern bean mosaic virus Species 0.000 description 1
- 241000701529 Soybean chlorotic mottle virus Species 0.000 description 1
- 241001508381 Subterranean clover stunt virus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000724318 Tenuivirus Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000723573 Tobacco rattle virus Species 0.000 description 1
- 241000723677 Tobacco ringspot virus Species 0.000 description 1
- 241000724291 Tobacco streak virus Species 0.000 description 1
- 241001148562 Tobacco stunt virus Species 0.000 description 1
- 241000723717 Tobravirus Species 0.000 description 1
- 241000710145 Tomato bushy stunt virus Species 0.000 description 1
- 241000016010 Tomato spotted wilt orthotospovirus Species 0.000 description 1
- 241001533336 Tombusviridae Species 0.000 description 1
- 241000710141 Tombusvirus Species 0.000 description 1
- 241000122134 Trichovirus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000710155 Turnip yellow mosaic virus Species 0.000 description 1
- 241000710136 Tymovirus Species 0.000 description 1
- 241001533358 Umbravirus Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 241000709760 Waikavirus Species 0.000 description 1
- 241001137667 White clover cryptic virus 1 Species 0.000 description 1
- 241001396914 White clover cryptic virus 2 Species 0.000 description 1
- 241000702661 Wound tumor virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Chemical class CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 230000016434 protein splicing Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 241001147420 ssDNA viruses Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 229940030325 tumor cell vaccine Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241001336411 unassigned viruses Species 0.000 description 1
- 241000709655 unidentified tobacco necrosis virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Definitions
- the present invention relates to an anti-cancer vaccine against Her2/Neu positive cancers, comprising a protein conjugate comprising a protein antigen from the extracellular domain of Her2/Neu or a protein antigen having a high sequence identity or similarity to a certain portion of the extracellular domain of Her2/Neu.
- the invention also relates to a protein antigen and a protein conjugate that comprises the protein antigen and, covalently bonded to the protein antigen, an immunogenic carrier.
- the protein conjugate or the protein antigen can be used as a cancer vaccine for Her2/Neu positive cancers.
- the cancer vaccine contains the protein conjugate and suitable adjuvants and/or pharmaceutically acceptable excipients. Further provided is a process of producing the protein conjugate. Further, the invention relates to a nucleic acid encoding the protein antigen, and a kit for producing the protein conjugate.
- Her2 Human Epidermal Growth Factor Receptor Her2, also known as Neu, ErbB-2, or p185, is a member of the epidermal growth factor receptor (EGFR/ErbB) family and encoded by the ERBB2 gene.
- EGFR/ErbB epidermal growth factor receptor
- HER2 HER2
- Her2 Her2/neu
- Her2 is a membrane-bound receptor tyrosine kinase composed of extracellular ligand binding domain, a transmembrane domain, and an intracellular domain that can interact with downstream signaling molecules.
- HER2 is considered to be an orphan receptor as it has no known ligand.
- HER2 can heterodimerise with other ErbB family receptors and is considered to be their preferred dimerisation partner. Dimerisation results in the autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptors and initiates a variety of signaling pathways leading to proliferation and inhibition of apoptosis.
- Amplification of the ERBB2 gene occurs in 20-30% of human breast and ovarian cancers and is linked to a more aggressive disease course and worse prognosis ( Bange, J., Zwick E. & Ullrich A., 2001, Nature Medicine, 7: 548-552 ; Slamon, D.J., Clark, G.M., Wong, S.G. et al., 1987' Science, 235:177-182 ; Slamon, D.J., Godolphin, W., Jones, L.A. et al., 1989, Science, 244:707-712 ; Berchuck, A., Kamel, A., Whitaker. R., et al., 1990, Cancer Research 50:4087-4091 ).
- the receptor can function on its own and/or it needs to heterodimerize with another ErbB member to transduce a deregulated proliferative signal responsible for the neoplastic behavior of the cells.
- HER2 has evolved as an important target for therapy of breast cancer in particular by monoclonal antibody therapy, e.g. Herceptin (trastuzumab) a humanized monoclonal antibody against this surface target has been approved by FDA in 1998. Herceptin has a significant impact on survival rates of HER2 positive breast cancer patients ( Tan, A. R. & Swain, S.M., 2002, Seminars in Oncology, 30: 54-64 ).
- trastuzumab is not effective against ligand-induced HER2 heterodimers ( Agus, D.B., Akita, R.W., Fox, W.D., et al., 2002, Cancer Cell, 2:127-137 ; Cho, H.S., Mason, K., Ramyar, K.X,, et al., 2003, Nature, 421:756-60 ). In addition, cancers usually develop resistance to trastuzumab ( Cho, H.S., Mason, K., Ramyar, K.X., et al., 2003, Nature, 421:756-760 ). While trastuzumab is efficient for the treatment of late stage metastatic cancers, it is not clear if it is effective in earlier stage cancers ( Editorial, 2005, Lancet, 366:1673 ).
- the key component of the vaccine is peptide E75, a peptide of 9-amino acid residues ( US 8,222,214 ; Mittendorf, E.A., Clifton, G.T., Holmes, J.P. et al., 2012, Cancer, 118:2594-602 ).
- Cancer vaccines do not usually cause toxicities typically associated with the use of therapeutic antibodies or chemotherapeutics (e.g. Peoples, G.E., Gurney, J.M., Hueman, M.T., et at., 2005, J. Clin.
- peptide-based vaccines In addition to a narrow spectrum of target sites for peptide vaccines, use of peptide-based vaccines might suffer from difficulties in identification of the most promising peptides. Peptide vaccines cause immune response limited to one or few peptides in the composition.
- a promising alternative are DNA vaccines that are easy to manufacture but, while they are superior to peptides in inducing CD8+ T-cell responses ( Chaise, C., Buchan, S.L., Rice, J. et al., 2008, Blood, 112:2956-2964 ; Rolla, S., Marchini, C., Malinarich, S. et al., 2008, Human Gene Therapy, 19:229-239 ; US8207141 ), they are typically less effective than protein vaccines in inducing antibody responses.
- HER2 protein-based vaccines were also carried out.
- the HER2 ICD intra-cellular domain, aa 676-1255
- was used as an adjuvant vaccine Disis, M.L., Schiffman, K., Guthrie, K. et al., 2004, J. Clin. Oncol., 22:1916-1925 . It was shown that the vaccine was well tolerated and the patients treated with the highest dose more rapidly developed immunity. No therapeutic effect was reported.
- Esserman et al., Cancer Immunol. Immunother (1999) 47: 337-342 relates to vaccination of neu transgenic mice with the extracellular domain (ECD) of HER2.
- ECD extracellular domain
- virosomes as a carrier system for Her2/neu cancer vaccines. Mice vaccinated with the extracellular domain (ECD) of the Her2/neu protein bound to virosomes generated a humoral and cytotoxic immune response. However, once tumors were formed in their mouse model, vaccination had no influence on tumor progression, i.e. had no therapeutic effect.
- ECD extracellular domain
- WO 2006/036550 A2 describes fusion proteins of a listeriolysin fragment with various fragments from HER-2.
- Example 1 of D1 among the HER-2 fragments are "EC2" and EC3" of amino acid residues 303-501 and 479-655, respectively, of rat HER-2.
- L. monocytogenes strains expressing the fusion proteins were generated (LM strains).
- LM strains L. monocytogenes strains expressing the fusion proteins
- HER-2-expressing tumor cells were injected subcutaneously into mice, whereupon tumors developed. Thereafter, recombinant LM strains were injected intraperitoneally into the mice for vaccination. Cessation of tumor growth was observed, as well as regression of tumors in some mice injected with LM strains. However, the vaccines do not induce a detectable antibody response.
- the cancer vaccines of the invention have the ability to induce a broad polyclonal antibodies response to human HER2 ECD, plus to recruit foreign T-cell help to enhance the humoral response via conjugation to a carrier such as tetanus Fragment C or plant RNA virus particles.
- the present invention not only provides preventive effects for cancer development, but also therapeutic effects by vaccination when tumors have already developed. No such therapeutic effects were achieved in the prior art.
- the protein conjugate used in the invention is a conjugate between the protein antigen and the immunogenic carrier (also referred to simply as "carrier").
- the protein antigen and the carrier are cross-linked, which means that they are linked by at least one covalent chemical bond. However, there may be multiple covalent bonds between one molecule of a protein antigen and a carrier particle or carrier molecule.
- the protein antigen is a protein that may consist of one amino acid sequence.
- the purpose of the protein antigen is to generate a polyclonal immune response against the extracellular domain of HER2/Neu.
- the purpose of the carrier is to generate a durable humoral or T cell-dependent immunity against HER2/Neu and to overcome tolerance against HER2/Neu.
- the protein conjugate can bring about a broad and durable humoral or T cell-dependent immunity against HER2/Neu positive cancers.
- the human HER2 protein of 1255 amino acids (SEQ ID NO: 18) has an N-terminal extracellular domain that is defined herein as to extend up to and including amino acid 653, a transmembrane domain of amino acids 654 to 675, and a C-terminal intracellular domain (ICD) from amino acids 676 to 1255 of SEQ ID NO: 18.
- the protein antigen is a protein comprising or consisting of a segment that can elicit an immune response against the HER2/Neu protein when the protein conjugate or the protein antigen is administered to a patient as a vaccine.
- This segment is also referred to herein as "first segment".
- a segment is a portion in the linear amino acid sequence of a protein.
- the protein antigen may consist of a segment that can elicit an immune response against the HER2/Neu protein.
- the protein antigen contains further portions or segments in addition to the segment that can elicit the immune response against the HER2/Neu protein.
- Such further portions or segments may be portions that function as a signal peptide or portions that allow easy purification of expressed protein antigen, such as a purification tag.
- Purification tags may be linked via linker peptides to the remainder of the protein antigen, whereby the linker may allow cleavage of the tags.
- Examples of purification tags are the 6x His-tag or the constant portion of an antibody light chain.
- the light chain may be a kappa light chain or a lambda light chain.
- the light chain is preferably taken from the species to be vaccinated. Since the main purpose of the invention is vaccination of humans, light chains from human antibodies are preferably used as purification tags.
- Preferred purification tags are the constant regions from antibody light chains, since they are abundant in the bloodstream of patients and therefore generally do not cause any adverse reactions. Thus, such purification tags do not need to be cleaved off from the protein antigen after expression and purification of the protein antigen.
- the segment (of the protein antigen) that can elicit an immune response against the HER2/Neu protein has a substantial length in order to generate a polyclonal immune response, preferably against multiple epitopes of the ECD of HER2/Neu.
- the protein antigen has a segment of substantial length taken from the ECD of the HER2/Neu protein or a segment of substantial length having a high sequence similarity or identity to a segment from the ECD of the HER2/Neu protein.
- the length of the segment is at least 300 amino acid residues, preferably at least 320 amino acid residues.
- the length is at most 400 amino acid residues. In preferred embodiments, the length is from 320 to 370 amino acids.
- the length of this segment is from 330 to 360 or from 337 to 350 amino acid residues.
- segment having 344 amino acids is used, which is referred to herein as "ED44", wherein “44” indicates the molecular of 44 kDa and “ED” stands for "extracellular domain”.
- the segment that can elicit an immune response against HER2/Neu may have an amino acid sequence taken from the ED of HER2/Neu that is given in SEQ ID NO: 1.
- the sequence segment of the protein antigen of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1 preferably comprises the amino acid sequence segment from amino acid 332 to 631, more preferably from amino acid 325 to 640, and even more preferably from amino acid 317 to 647, of SEQ ID NO:1 or variant sequence segments as defined in items (ii) or (iii).
- the protein antigen does generally not contain further sequence segments having a sequence identity of more than 50% to any sequence segment of the HER2 protein.
- the protein antigen has a sequence segment of 300, preferably of 330, more preferably of 337, or more contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 2.
- the protein antigen does generally not contain further sequence segments having a sequence identity of more than 50% to any sequence segment of the HER2 protein.
- sequence identity to a sequence portion of SEQ ID NO: 1 or SEQ ID NO: 2 does not need to be 100%.
- the sequence segment may be a variant having an amino acid sequence having at least 90% sequence identity to a sequence portion from SEQ ID: 1 and SEQ ID: 2.
- the amino acid sequence identity may be at least 95% and preferably at least 97%. In calculating percent sequence identity, two sequences are aligned and the number of identical matches of nucleotides or amino acid residues between the two sequences is determined.
- the number of identical matches is divided by the length of the aligned region (i.e., the number of aligned nucleotides or amino acid residues) and multiplied by 100 to arrive at a percent sequence identity value. Possible and preferred lengths of the sequence segment (aligned region) are as defined above.
- the sequence segment may be a variant having an amino acid sequence having at least 91% sequence similarity to a sequence portion from SEQ ID: 1 or SEQ ID: 2.
- the amino acid sequence identity may be at least 91%, preferably at least 94%, more preferably at least 97% and even more preferably at least 99%. Possible and preferred lengths of the aligned region are as defined above.
- Amino acid sequence similarities and identities may be determined using BLASTX 2.2.14 using the standard settings. The standard settings allow, for example, for sequence gaps in alignments.
- the variant sequence segment of the protein antigen may have from 1 to 20 amino acid additions, substitutions or deletions compared to a sequence portion from SEQ ID: 2 over the length of the segment, provided the variant sequence can still elicit formation of antibodies against the ECD of human HER2 protein when injected into an animal (such as a rat or a mouse).
- the maximum number of amino acid additions, substitutions or deletions may be at most 10, preferably at most 5, whereby the total number of additions, substitutions and additions together determine the number of "amino acid additions, substitutions or deletions". These numbers of additions, substitutions and additions occur over the length of the sequence segment of 300 or more amino acid residues. Preferred lengths are as those given above.
- Substitutions may take place at those positions in the amino acid sequence where an aligned rat and human HER2 protein deviate, such as in the alignment shown in Fig. 2 . This is based on the fact that antibodies against the ECD of rat HER2 protein are cross-reactive with the ECD of the human HER2 protein and vice versa.
- amino acids at one or more of the following positions of SEQ ID NO:1 may be substituted by residues of other amino acids: 317, 318, 352, 353, 356, 353, 359, 361, 365, 387, 398, 390, 394, 420, 429, 430, 451, 452, 470, 472, 497, 498, 502, 503, 505, 506, 510, 512, 513, 517, 533, 547, 548, 556-559, 572, 574, 579, 585, 593-595, 622, 639, 640, 651.
- the variant sequence segment may have the minimum sequence identities or similarities to 2 and from 1 to 20, preferably from 1 to 10, more preferably from 1 to 5 additions and/or deletions, allowing for optimized alignment when determining the sequence identity or similarity.
- the variant sequence segment may have the minimum sequence identities to SEQ ID NO: 1 or 2 and from 1 to 10 additions and/or deletions.
- the variant sequence segment of the protein antigen may be encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid that is complementary to a nucleic acid sequence encoding SEQ ID: 1 or SEQ ID: 2.
- the hybridization conditions depend on the G/C composition of DNA probe and salt concentration in hybridization buffer. For hybridization usually different concentrations of SSC buffer are used. 1xSSC buffer contains 150 mM NaCl, 15 mM trisodium citrate, pH 7.0.
- the hybridization results are directly related to the hybridization stringency, e.g. number of degrees below the Tm (melting temperature) of DNA at which the experiment is performed. Higher number of degrees below the Tm corresponds weaker hybridization stringency.
- Tm 69.3°C + 0.41(% G + C)°C.
- stringent conditions are, for example, conditions wherein the hybridization takes place in 1x SSC containing 0.1% SDS at 60°C.
- the protein antigen and, preferably, the protein conjugate used in the invention preferably do not contain a further amino acid sequence segment as follows: a further amino acid sequence segment of 20 or more, preferably 10 or more, contiguous amino acid residues from a sequence portion from amino acid 1 to 253, preferably 1 to 283, more preferably 1 to 300, nor from a sequence portion starting from amino acid 670, preferably from amino acid 654, to amino acid 1255 of SEQ ID NO: 18; or a further amino acids sequence segment of more than 20 contiguous amino acid residues having more than 50%, preferably more than 40%, sequence identity to a sequence portion from amino acid 1 to 253, preferably 1 to 283, more preferably 1 to 300, nor to a sequence portion starting from amino acid 670, preferably from amino acid 654, to amino acid 1255 of SEQ ID NO: 18.
- the protein antigen, and the protein conjugate containing the protein antigen do not contain an amino acid sequence segment of 10 or more, preferably of 5 or more, contiguous amino acid residues from the transmembrane domain or the intracellular domain of the Her2/neu protein of SEQ ID NO: 18.
- any further sequence segment (of the protein antigen) of a length of at least 7 amino acid residues of said protein antigen has an amino acid sequence identity less than 50% to any sequence portion of identical length of SEQ ID NO: 18.
- the protein antigen consists of a first sequence segment that can elicit the immune response against the HER2 protein and optionally a further sequence segment, wherein said first sequence segment
- the protein antigen and the immunogenic carrier are preferably covalently bonded by chemical cross-linking using a chemical cross-linking agent.
- the protein antigen may be cloned and expressed according to generally known methods. However, expression is preferably done in eukaryotic cells. A nucleic acid encoding the desired portion or the first segment from the extracellular domain of HER2/Neu may be cloned using primers designed for such portion using the known gene sequence of the HER2 gene.
- GenBank accession no. for the Her2/neu gene is: AAA75493 (SEQ ID NO: 18).
- Many different expression systems that are based on different production hosts (bacteria, fungi, animal, insect and plant cells) and expression vectors designed either for stable transgenic or transient expression can be used. All such systems are well known to the skilled person and described (for review see: Huang, C.J., Lin, H.
- plant expression systems Another important advantage of plant expression systems is the ability to provide for the production of plant viral particles by allowing expression of plant viral coat protein or fusion proteins from the expression vector ( Werner, S. et al., 2006, Proc. Natl. Acad. Sci. USA, 103:17678-17683 ; WO2007031339 ).
- Such systems are described in detail in numerous research articles, reviews and patents ( Marillonnet, S., Thoeringer, C., Kandzia, R. et al., 2005, Nat. Biotechnol., 23:718-723 ; Giritch, A., Marillonnet, S., Engler, C., et al., 2006, Proc. Natl. Acad. Sci.
- the ED44 of human Her2/neu (amino acid residues 310 - 653; Fig 1A ) and its two truncated variants (amino acid residues 310-649 and 340-649; Fig 1C, D ) have been cloned into viral vectors, tested for the expression level and were used for conjugate generation and vaccine formulation.
- the protein antigen After expression of the protein antigen preferably in a eukaryotic host, it is purified using generally known methods.
- the protein antigen has a purification tag. Purification can then involve column chromatography using a matrix having affinity to the purification tag.
- the immunogenic carrier may have a molecular weight of at least 5 kDa, preferably of at least 10 kDa, more preferably at least 15 kDa, and even more preferably of at least 20 kDa. The molecular weight may, however, still be much larger than 20 kDa and may be higher than 100 kDa.
- the carrier may or may not be a protein. Preferably, however, the carrier is also a protein.
- the carrier protein may be a monomeric protein such as tetanus toxin fragment C or the DOM1 fragment (SEQ ID NO: 17) thereof or a multimeric protein. Multimeric proteins may be di-, tri or higher oligomers or even polymers of protein subunits.
- a widely used carrier that is a polymeric protein is Keyhole Limpet Hemocyanine (KLH) ( Harris, J.R. & Markl, J. 1999, Micron., 30: 597-623 ; Harris, J.R. & Markl, J. 2000, Eur. Urol., 3: 24-33 ).
- KLH Keyhole Limpet Hemocyanine
- examples of other polymeric proteins are viral particles that may consist of or comprise a large number of monomeric protein molecules or subunits, generally multimers of coat protein monomers. Such viral particles may contain viral RNA or DNA.
- Viral particles are preferred carriers, since they are highly immunogenic, notably in mammals such as humans, and can cause a strong immune response.
- the viral particles are plant viral particles, such as of plant tobamoviruses.
- Viral particles, notably plant viral particles, that may be used as immunogenic carriers in the protein conjugate of the invention are described in more detail in the following.
- a viral particle is a multimeric particle comprising a plurality of viral coat protein molecules.
- the sizes of the viral particles as determined in electron microscopy as described in Analytical Biochem., 333 (2004) 230-235 may be at least 10 nm in the shortest dimension, more preferably at least 13 nm in the shortest dimension.
- viral particles are generally formed of many coat protein molecules.
- the viral particles notably the plant viral particles, can be formed by expressing the coat protein molecules in a suitable host such as in a plant or cells thereof as desribed in WO 2007/ 031339 or by purifying plant viral particles from a plant host that is infected with the plant virus.
- Plant viruses the plant viral particles of which may be used in the protein conjugate of the present invention, are known, see e.g. the book of Drews, Adam, Heinze, "Molekulare Devirologie", Springer-Verlag Berlin, Heidelberg 2004 .
- the viral particles may be produced by expressing a polynucleotide encoding the (monomeric) protein, generally the coat protein, that assembles for forming the viral particle in a bacterial or plant host.
- the plant host may be plant cells, plant tissue or entire plants. Apart from encoding the coat protein, said polynucleotide will have regulatory elements required for the expression of the coat protein in the chosen host.
- the viral particles of the invention Upon expressing the polynucleotide, the viral particles of the invention generally assemble within host cells or may be assembled in vitro after isolating the coat protein from the host cells under suitable conditions.
- the plant viral coat protein may be derived from any plant virus such as the plant viruses listed below.
- said plant viral coat protein is derived from a plant virus forming rod-shaped viral particles.
- Other examples are filamentous and icosahedral plant viral particles.
- Being derived means that the coat protein that forms the plant viral particle does not have to be identical to the natural coat protein of a plant virus. Instead, the coat protein used may have additions, deletions, insertions or mutations relative to a natural coat protein of a plant virus.
- at most 20 amino acid residues of the natural plant viral coat protein are deleted and/or mutated.
- at most 20 amino acid residues are inserted into the natural sequence of the plant viral coat protein of the plant virus from which the coat protein is derived.
- the plant viral particle (and the plant viral coat protein that forms the plant viral particle) and the plant viral particle may be derived from an RNA virus, such as a plant plus-sense single-stranded RNA virus, or from a DNA virus.
- plant viruses the coat protein of which may be used for the present invention include tobamoviruses such as tobacco mosaic virus (TMV), turnip vein clearing virus (TVCV), potato virus X, potato virus Y and fragments or homologues thereof, provided said fragments or homologues are capable of forming viral particles.
- TMV tobacco mosaic virus
- TVCV turnip vein clearing virus
- potato virus X potato virus Y
- fragments or homologues are capable of forming viral particles.
- the coat protein used has a sequence identity of at least 50% to the coat protein of turnip vein clearing virus, to tobacco mosaic virus, potato virus X or potato virus Y.
- said sequence identity is at least 60%; in a further embodiment, said sequence identity is at least 70%.
- the coat protein has a sequence identity
- Plant viruses belonging to different taxonomic groups that form viral particles can be used as immunogenic carriers according to the principles of the present invention. This is right for both RNA- and DNA-containing viruses, examples for which are given in the following. Names of orders, families and genera are in italic script, if they are approved by the ICTV. Taxa names in quotes (and not in italic script) indicate that this taxon does not have an ICTV international approved name. Species (vernacular) names are given in regular script. Viruses with no formal assignment to genus or family are indicated):
- Rod-shaped viruses - TMV the virions have ⁇ 300 nm in length and ⁇ 18 nm in diameter
- PVX filamentous; usually flexuous; with a clear modal length
- Brome Mosaic Virus 26 nm in diameter.
- Symmetry/shape - icosahedral Alfalfa mosaic virus (Nucleocapsids bacilliform, or quasi-isometric elongated): 35 nm long (Tb) or 30 nm long; Ta that occurs either in bacilliform (Ta-b) or ellipsoidal (Ta-t) shape) with no clear modal length: 56 nm long (B); 43 nm long (M); 18 nm in diameter.
- Preferred plant viral particles are from plant viruses having a single-stranded plus-sense RNA genome.
- the viruses tobacco mosaic virus and potato virus X
- the viruses may be expressed using well-established expression systems for said viruses ( Donson et al., 1991, Proc Natl Acad Sci U S A, 88:7204-7208 ; Shivprasad et al., 1999, Virology, 255:312-323 ; Marillonnet et al., 2004, Proc Natl Acad Sci U S A, 101:6852-6857 ; Marillonnet et al., 2005, Nat Biotechnol., 23:718-723 ; Chapman, Kavanagh & Baulcombe, 1992, Plant J., 2:549-557 ; Baulcombe, Chapman & Santa Cruz, 1995, Plant J., 7:1045-1053 ; Angell & Baulcombe, 1997, EMBO J., 16:3675-3684 ) including the very
- Plant viral particles from other viruses including DNA viruses also can be used for practicing this invention (for reviews please refer to: Mullineaux et al., 1992, Genetic Engineering in Plant Viruses, CRC Press Inc., pp187-215 ; Timmermans et al., 1994, Ann. Rev. Plant Physiol. Plant Mol. Biol., 45:79-112 ; Porta & Lomonossoff, 2002, Biotechnol. Genet. Engineering Rev., 19:245-291 ).
- the immunogenic carrier may be a plant viral particle that may be derived from an RNA virus, such as a Tobamovirus.
- the immunogenic carrir is a plant viral particle of a virus from the family Potyviridae. Other options were mentioned above.
- Multimeric carrier proteins may be covalently bonded to multiple protein antigen molecules, e.g. as illustrated in Fig. 3C .
- a viral particle as a carrier may be covalently bonded to multiple molecules of the protein antigen.
- liposomes for review see: Felnerova, D., Viret, J.F., Rob, R., et al., 2004, Curr Opin Biotechnol., 15: 518-29 ; Tiwari, S., Agrawal, G.P. & Vyas, S.P. 2010, Nanomedicine, 5: 1617-1650 ).
- Carrier proteins may be expressed as generally known in the art, e.g using expression systems such as those mentioned above. Expression of plant viral coat protein and production of plant viral particles is described in detail in WO2007031339 . Other carriers are commercially available such as Tetanus toxin fragment C from Sigma-Aldrich (T3694 Sigma) or from Merck-Millipore (No. 582235). As a further alternative, a part of Tetanus toxin fragment C called DOM1 (see SEQ ID NO: 17) can be used.
- DOM1 is a novel antigen for B cells in patients and hence would not be recognised by pre-existing antibodies induced because of a tetanus vaccination ( Low, L., Manderr, A., McCann, K. et al., 2009, Human Gene Ther., 20:1269-1278 ), that supposedly might slow down the immune response.
- the protein conjugate comprising the protein antigen and the carrier protein may be expressed as a fusion protein, i.e. as portions of one amino acid sequence.
- the covalent bond between the protein antigen and the carrier protein is a peptide bond of the fusion protein.
- a linker peptide may be used in between the protein antigen and the carrier protein for allowing independent folding of the protein antigen domain and the carrier protein domain of the fusion protein.
- WO2007031339 describes how protein antigen as a recombinant protein co-expressed as a fusion protein with plant viral coat protein. Coat protein domains may then assemble, optionally in the presence of free viral coat protein, to form plant viral particles displaying on their surface protein antigen domains.
- the immunogenic carrier protein preferably does not have similarity to the HER2 protein.
- the carrier protein does preferably not have an amino acid sequence segment of 50 or more, preferably of 30 or more, more preferably of 20 or more, and even more preferably of 10 or more contiguous amino acid residues, which sequence segment has an amino acid sequence identity of more than 50% to any sequence portion of identical length (in terms of number of amino acid residues) of SEQ ID NO: 18.
- Covalent linking of two or more different proteins or peptides can be achieved using several well-known approaches. These are not limited to: translational fusion; intein-mediated cis- or trans-splicing, hetero-oligomeric proteins assembly via disulfide bonds formation, chemical conjugation using cross-linking agents.
- Covalent in-frame fusion of two or more different proteins or protein fragments can be achieved by using intein-mediated trans-splicing.
- Inteins were first identified as protein sequences embedded in-frame within protein precursor and excised during protein maturation process ( Perler, F.B., Davis, E.O., Dean, G.E. et al., 1994, Nucleic Acids Res., 22:1125-1127 ; Perler, F. B. , 1998, Cell, 92:1-4 ). All information and catalytic groups necessary to perform a self-splicing reaction reside in the intein and two flanking amino acids. The chemical mechanism of protein splicing is described in detail by Perler and colleagues (1997, Curr. Opin. Chem.
- Inteins usually consist of N-and C-terminal splicing regions and central homing endonuclease region or small linker region. Over 100 inteins are known so far that are distributed among the nuclear and organellar genomes of different organisms including eukaryotes, archaebacteria and eubacteria (http://www. neb. com/neb/inteins. html). Engineering of split inteins is described for example in Brenzel, S., Kurpiers, T. & Mootz, H.D. 2006, Biochemistry, 45:1571-1578 ).
- trans-splicing systems in which the N-terminal and C-terminal fragments of intein are co-expressed as separate fragments and, when fused to exteins (protein fragments, being ligated together with the help of intein), can perform trans-splicing in vivo ( Shingledecker, K., Jiang, S.Q. & Paulus, H., 1998, Gene, 207:187-195 ).
- intein sequences encoded by those genes reconstitute a split mini-intein and are able to mediate protein trans- splicing activity when tested in Esherichia coli cells.
- the intein molecule of the same origin (DnaE intein from Synechocystis sp. strain PCC6803) was used to produce functional herbicide-resistant acetolactate synthase 11 from two unlined fragments ( Sun, L., Ghosh, I., Paulus, H. et al., 2001, Appl. Environ.
- Yet another way of linking two or more polypeptides together is their assembly via disulfide bond formation.
- the easiest way to achieve this is to use fragments of proteins that are known to interact between each other and, preferably, to form disulfide bonds.
- fragments are the constant regions of immunoglobulin light (e.g. "kappa” or “lambda") and heavy (e.g. Fc of IgG) chains.
- This approach can be used for formation of homodimers consisting of antigen fusion to constant regions heavy chain ( US7067110 ) and for bi-specific IgG design ( Zuo,Z., Jimenez, X., Witte, L. & Zhu, Z.
- cross-linking agents which is preferred for linking the protein antigen and the carrier protein in the present invention.
- Various known cross-linking agents can be applied for this purpose.
- Frequently employed cross-linking agents are glutaraldehyde ( Maloney, D.G., Kaminski, M.S., Burowski, D. et. al., 1985, Hybridoma, 4:192-209 ; Timmerman, J.M. & Levy, R., 2000, J. Immunol., 164:4797-47803 ; Bendandi, M., Gocke, C.D., Kobrin, C.B. et. al., 1999, Nat.
- Glutaraldehyde crosslinks proteins primarily via lysine residues, with secondary reactions at cysteine, tyrosine, and histidine residues ( Migneault, I., Dartiguenave, C., Bertrand, M.J. & Waldron, K.C., 2004, Biotechniques, 37:790-796 ).
- Maleimide acts on (reduced) cysteine sulfhydryl groups ( Betting, D.J., Kafi, K., Abdollah-Fard, A. et al., 2008, J. Immunol., 181:4131-4140 ).
- cross-linking agents are well-known to those familiar with the art and are described in many reviews and protocols ( Wong, S.S. & Wong, L.J. 1993, Enzyme Microb. Technol., 14:866-874 ; Wong, S.S. & Jameson, D.M. 2009, Chemistry of Protein and Nucleic Acid Cross-Linking and Conjugation, CRC Press, Second Editi on; Thermo Scientific Pierce Crosslinking Technical Handbook, 2009, Thermo Scientific ; for downloading more info or protocols - www.thermo.com/pierce).
- Cross-linking agents are also commercially available and the protocols for cross-linking proteins of the manufacturer may be followed.
- the protein conjugate may be produced by a process comprising providing the protein antigen and the immunogenic carrier as separate protein molecules and cross-linking the protein antigen and the immunogenic carrier via a linker using a chemical cross-linking agent such as glutaraldehyde.
- the kit of the invention comprises the protein antigen as defined herein and an immunogenic protein or protein aggregate for cross-linking with said protein antigen for forming the protein conjugate.
- the kit may further contain a chemical cross-linking agent.
- the protein conjugate obtained as described above is generally stored in an aqueous medium. For longer storage times, it may be frozen or lyophilized.
- the aqueous medium may contain a buffer to control the pH and may contain physiologic saline and/or other additives.
- the anti-cancer vaccine of the invention contains the protein conjugate of the invention and suitable pharmacologically acceptable excipients.
- the anti-cancer vaccine contains the protein antigen, whereby the protein antigen may not be covalently linked to an immunogenic carrier or an immunogenic carrier protein, and suitable pharmacologically acceptable excipients.
- the invention also provides a vaccine comprising a protein antigen as described herein, wherein the protein antigen of item (ii) or item (iii) is capable of providing protection against a HER-2/Neu-positive cancer, in particular therapeutic protection after tumor formation as determined in the Balb-NeuT metastatic breast cancer model.
- the anti-cancer vaccine is generally a liquid aqueous formulation.
- the anti-cancer vaccine may also be in solid form such as in a lyophilized form to be reconstituted with an aqueous medium before administration.
- excipients include, without limitation, sterile aqueous solutions, suspensions, and emulsions.
- Aqueous excipients include, without limitation, water, alcohol, saline, and buffered solutions.
- Preservatives and other additives such as, for example, antimicrobials, anti-oxidants, chelating agents may also be present.
- the anti-cancer vaccine can comprise agents that enhance the protective efficacy of the vaccine, such as adjuvants.
- adjuvants include any compound or compounds that act to increase a protective immune response to the protein conjugate, thereby reducing the quantity of antigen necessary in the vaccine, and/or the frequency of administration necessary to generate a protective immune response.
- Adjuvants can include for example, emulsifiers, muramyl dipeptides, pyridine, aqueous adjuvants such as aluminum hydroxide, aluminum salts, chitosan-based adjuvants, and any of the various saponins, oils, and other substances known in the art, such as Amphigen, LPS, bacterial cell wall extracts, bacterial DNA, CpG sequences, synthetic oligonucleotides and combinations thereof ( Schijns et al. (2000) Curr. Opin. Immunol. 12:456 ), Mycobacterial phlei (M. phlei) cell wall extract (MCWE) ( U.S. Pat. No. 4,744,984 ), M.
- aqueous adjuvants such as aluminum hydroxide, aluminum salts, chitosan-based adjuvants, and any of the various saponins, oils, and other substances known in the art, such as Amphigen, LPS, bacterial cell wall extracts,
- phlei DNA M-DNA
- M-DNA-M. phlei cell wall complex MCC
- emulsifiers include natural and synthetic emulsifying agents, as well as anionic, cationic and nonionic compounds.
- anionic emulsifying agents include, for example, the potassium, sodium and ammonium salts of lauric and oleic acid, the calcium, magnesium and aluminum salts of fatty acids, and organic sulfonates such as sodium lauryl sulfate.
- Synthetic cationic agents include, for example, cetyltrhethylammonlum bromide, while synthetic nonionic agents are exemplified by glycerylesters (e.g., glyceryl monostearate), polyoxyethylene glycol esters and ethers, and the sorbitan fatty acid esters (e.g., sorbitan monopalmitate) and their polyoxyethylene derivatives (e.g., polyoxyethylene sorbitan monopalmitate).
- Natural emulsifying agents include acacia, gelatin, lecithin and cholesterol.
- Suitable adjuvants can be formed with an oil component, such as a single oil, a mixture of oils, a water-in-oil emulsion, or an oil-in-water emulsion.
- the oil can be a mineral oil, a vegetable oil, or an animal oil.
- Mineral oils are liquid hydrocarbons obtained from petrolatum via a distillation technique, and are also referred to in the art as liquid paraffin, liquid petrolatum, or white mineral oil.
- Suitable animal oils include, for example, cod liver oil, halibut oil, menhaden oil, orange roughy oil and shark liver oil, all of which are available commercially.
- Suitable vegetable oils include, for example, canola oil, almond oil, cottonseed oil, corn oil, olive oil, peanut oil, safflower oil, sesame oil, or soybean oil.
- FCA Freund's Complete Adjuvant
- FIA Freund's Incomplete Adjuvant
- FCA and FIA are water-in-mineral oil emulsions; however, FCA also contains a killed Mycobacterium sp.
- Immunomodulatory cytokines can also be used in the vaccine compositions to enhance vaccine efficacy, for example, as an adjuvant.
- Non-limiting examples of such cytokines include interferon alpha (IFN- ⁇ ), interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF), or combinations thereof.
- GM-CSF is preferred as a cytokine.
- the anti-cancer vaccine of the invention can be used for treating or preventing HER-2/Neu-positive cancer in mammals, preferably in humans. Treating HER-2/Neu-positive cancer is preferred over prevention thereof. Treatment means that the vaccine is administered to a subject having the cancer. Preferred anti-cancer vaccines of the invention have a therapeutic effect, which means that further development of a HER-2/Neu-positive cancer can be prevented or slowed down even if the vaccine is administered when the cancer has already formed in the patient. In the examples, therapy is investigated and demonstrated in experiments referred to as "therapeutic setting".
- HER-2/Neu-positive cancers can be HER-2/Neu-positive, such as breast, liver, kidney, pancreatic, ovarian, prostate, gastric, colon, colorectal, bladder, testicular, stomach, esophageal or thyroid cancer.
- Detection of the HER2 gene or protein in these cancers may be e.g. by an immune reaction in biopsies using anti-HER-2/Neu monoclonal or polyclonal antibodies or by determining expressed RNA from the HER2 gene. Amplification of the HER2 gene was tested in Science 235 (1987) 177-182 and correlated with the prognosis of breast cancer.
- the anti-cancer vaccine is administered to the patient.
- Administration of the vaccine can be by infusion or injection (e.g., intravenously, intramuscularly, intracutaneously, subcutaneously, intrathecal, intraduodenally, intraperitoneally, and the like).
- the compositions or vaccines are administered by intradermal injection.
- the anti-cancer vaccine is administered to a patient in a therapeutically effective amount.
- the amount depends on the several variables such as the size or weight of the patient and condition of the patient.
- Toxicity and therapeutic efficacy of the vaccine can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in patients.
- the dosage of such vaccine compositions lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
- the vaccine can be administered to a patient on any schedule appropriate to induce and/or sustain protective immunity against the cancer, and more specifically to induce and/or sustain a humoral and preferably a cytotoxic T lymphocyte response to the protein antigen.
- patients can be administered a vaccine composition as a primary immunization as described and exemplified herein, followed by administration of a booster to bolster and/or maintain the protective immunity.
- patients can be administered the vaccine compositions 1, 2 or more times per month. Once per month for six consecutive months is preferred to establish the protective immune response, particularly with respect to the primary immunization schedule.
- boosters can be administered at regular intervals such as every 6 or more months after completion of the primary immunization schedule.
- Administration of the booster may be every 6 months.
- the vaccine administration schedule including primary immunization and booster administration, can continue as long as needed for the patient, for example, over the course of several years, to over the lifetime of the patient.
- the vaccine schedule includes more frequent administration at the beginning of the vaccine regimen, and includes less frequent administration (e.g., boosters) over time to maintain the protective immunity.
- the vaccine of the invention may be administered to a human patient in a dosage of from 0.1 mg to 50 mg of the sequence segment of 300 or more contiguous amino acids from the ECD of the HER2 protein or of the variant sequence segment of the protein antigen per administration. Such dosage may also be used in subsequent administrations.
- Fragment C serves as immunogenic carrier protein in the vaccine which aids to break the self-tolerance for HER2.
- Tetanus toxin is a potent neurotoxin produced by Clostridium tetani the causative agent of tetanus.
- the Tetanus toxin fragment C sequence was generated by gene synthesis. Also here, from the originally synthesized fragment C sequence different modules were generated using PCR ( Fig. 10-11 ).
- the Her2-ED44 and Tetanus toxin fragment C modules were cloned in TMV-based viral expression vectors (magnICON® system, see below) using the Type IIS restriction enzyme Bsa I which generates different, customized overhangs for each module and thereby allowing assembly of the final construct by removing these restriction sites ( Engler, C., Kandzia, R. & Marillonnet, S. 2008, PLoS One, 3:e3647 ; Fig. 4 , Fig. 7 , Fig. 10 ).
- the TMV-based viral vector constructs also contained a rice ⁇ -amylase 3A signal peptide (Swiss-Prot accession no.: P27932) which is cleaved off in planta and serves to deliver the protein of interest in the plant apoplast where it accumulates.
- the rice ⁇ -amylase signal peptide was amplified from Oryza sativa genomic DNA and the last two amino acids of the signal peptide modified from HA to SG (wild type: MGKQMAALCGFLLVALLWLTPDVA HA ; modified: MGKQMAALCGFLLVALLWLTPDVA SG ) due to cloning reasons.
- Her2-ED44 and Tetanus toxin fragment C were fused to a (GGGGS) 3 linker and a 6x His tag or human kappa light chain constant region (Swiss-Prot accession no.: P01834) which was optimized by gene synthesis for N. tabacum codon usage ( Fig. 4-11 ).
- TMV particles As an alternative immunogenic carrier, Tobacco Mosaic Virus (TMV) particles were used. TMV particles have a rod-like structure of approximately 300 nm in length and 18 nm in diameter. The particles are built of coat protein (CP) subunits which assemble around the genomic, single-stranded RNA of the virus. To improve the conjugation efficiency by glutardialdehyde, the coat protein was modified. The N-terminal modification of the TVCV coat protein (Swiss-Prot accession no.: Q88922), i.e.
- Viral binary expression vectors were developed based on the magnICON® technology ( Gleba, Y., Klimyuk, V. & Marillonnet, S., 2005, Vaccine, 2005, 23:2042-2048 ; Gleba, Y., Klimyuk, V. & Marillonnet, S. 2007, Curr. Opin. Biotechnol., 18:134-141 ) using elements from Tobamo viruses (Tobacco Mosaic Virus, TMV), i.e. from the cDNAs of two closely related plant viruses, TVCV (turnip vein clearing virus; Lartey, R.T., Lane, L.C. & Melcher, U. 1994, Arch.
- TMV Tobamo viruses
- TVCV turnip vein clearing virus
- the resulting vectors are called 'TMV-based', since both parental viruses are tobamoviruses and related to the well-known tobacco mosaic virus (TMV). All three viruses (TVCV, crTMV and TMV) are positive-strand RNA viruses and have the same overall structure and mode of replication.
- the viruses encode an RNA-dependent RNA polymerase (RdRP), the Movement Protein (MP) and the Coat Protein (CP).
- RdRP replicates the full viral RNA transcript (genomic RNA) as well as the two subgenomic RNAs (sgRNAs) that are required for expression of the two other viral proteins, MP and CP.
- the MP is required for short distance cell-to-cell movement of the viral genomic RNA within the infiltrated leaf.
- the CP is required for formation of viral particles and long distance systemic movement from leaf to leaf via the vascular system. Formation of viral particles is not required for cell-to-cell movement. Therefore, the CP was eliminated from the viral vectors and replaced with the gene of interest.
- the viral vector is unable to produce viral particles and the gene of interest is expressed at higher levels.
- the viral vector must also contain the 5' and 3' non-translated (5' ntr and 3' ntr) viral sequences which are essential for replication ( Marillonnet, S., Giritch, A., Gils, M. et al., 2004, Proc. Natl. Acad. Sci. U S A., 101:6852-7 ; Fig. 13 ).
- the cDNA of the viral vector has been cloned between a plant promoter and a plant terminator (Act2 and nos) ( Marillonnet, S., Giritch, A., Gils, M. et al., 2004, Proc. Natl. Acad. Sci. U S A., 101:6852-6857 ) and plant introns were added within the RdRP and MP sequences ( Marillonnet, S., Thoeringer, C., Kandzia, R. et al., 2005, Nat. Biotechnol., 23:718-723 ).
- the complete viral vector (plant promoter, TMV-based viral vector sequences with gene of interest, plant terminator) has been cloned between the T-DNA left and right borders of a binary vector.
- the elements of the binary vector are a pVS1 origin ( Hajdukiewicz, P., Svab, Z. & Maliga, P., 1994, Plant Mol Biol., 25:989-994 ) for plasmid replication in Agrobacterium, a co /E1 origin for plasmid replication in E .
- coli a npt III kanamycin antibiotic resistance gene ( Frisch, D.A., Harris-Haller, L.W., Yokubaitis, N.T. et al., 1995, Plant Mol. Biol., 27:405-409 ) and T-DNA left and right borders ( Frisch, D.A., Harris-Haller, L.W., Yokubaitis, N.T. et al., 1995, Plant Mol. Biol., 27:405-409 ) to delimitate the ends the DNA transferred to plant cells.
- a lac Z ⁇ cassette amplified from pUC19 was inserted between two Bsa I restriction sites which allow seamless in frame cloning of the gene of interest. Therefore, during initial construction of the viral vectors, all naturally occurring Bsa I recognition sites were removed to allow easy and robust cloning of the gene of interest ( Fig. 13 ).
- the selected Agrobacterium strain harboring the TMV-based expression vector is grown in liquid LBS medium with soya peptone (Duchefa Biochemie, Haarlem, The Netherlands) replacing tryptone, and supplemented with 50 ⁇ g/mL rifampicin and 50 ⁇ g/mL kanamycin.
- Agrobacterial cultures are grown at 28°C until OD 600 reaches 2 to 4.
- Infiltration solution is prepared by diluting the agrobacterial culture in infiltration buffer (10 mM MES, pH 5.5, 10 mM MgSO 4 ) to a defined cell concentration (equivalent to a 200-fold dilution of a culture with OD 600 of 1.0).
- Nicotiana benthamiana plants (5 to 10 for harvest of TMV particles), grown under controlled and standardized conditions for 6-8 weeks, are vacuum-infiltrated with the agrobacterial infiltration solution and then kept in the greenhouse for 7-12 days for expression and accumulation of the recombinant protein. Plant leaves are then harvested, ground in liquid nitrogen to a fine leaf powder and kept at -80°C until protein extraction followed by purification.
- the leaf powder (0.6 to 1 kg) is extracted in 20 mM sodium phosphate, pH 6.0, 0.5 M NaCl, 10 mM imidazole with approximately two volumes (w/v) of extraction buffer.
- the extraction is performed at +4°C by shaking for 40 minutes.
- the homogenate is clarified by centrifugation at 15.000 x g for 10 minutes followed by filtration through MiraCloth filter.
- the pelleted plant tissue is re-extracted using the same extraction conditions.
- the extracts are combined and subjected to pH adjustment.
- the pH of the clarified homogenate is lowered to 5.0 using 5N HCL for removal of host cell proteins including Rubisco.
- the pH of the crude extract is re-adjusted to pH 7.4 with 5N NaOH.
- the crude extract is then centrifuged (20.000 x g for 15 minutes) to remove cell debris and precipitates.
- the crude extract is filtered through several filtration membranes (20 ⁇ m - 8 ⁇ m - 3 ⁇ m - 0.45 ⁇ m). The clear filtrate is applied onto a 5 mm HisTrapTM FF column (GE Healthcare, 17-5255-01), which was equilibrated with 20 CV washing buffer (20 mM sodium phosphate pH 7.5, 0.5 M NaCl, 20 mM imidazole).
- Her2-ED44-His is eluted with 20 CV elution buffer (20 mM sodium phosphate pH 7.5, 0.5 M NaCL, 0.5 M imidazole). A polishing step is applied to remove DNA, host cell proteins and endotoxins.
- the eluted Her2-ED44-His solution is subjected to a SartobindQ®SingleSep mini capsule (Sartorius, #92IEXQ42D4-SS), which is a strong basic anion exchanger.
- the SartobindQ®SingleSep mini capsule is sanitized with 1 N NaOH followed by equilibration with PBS pH 5.0.
- the pH of Her2-ED44-His eluate is adjusted to pH5.0 using 5 N HCL.
- the flow-through of SartobindQ®SingleSep mini capsule is collected and the capsule is washed with PBS buffer, pH 5.0, until base line UV280 nm is reached.
- the purified Her2-ED44-His is concentrated using Spin-X UF concentrator 30k MWCO (Corning, #431489). Finally, the concentrate is sterile-filtrated using 0.2 ⁇ m filter.
- the protein concentration of purified Her2-ED44-His is determined using BCA protein assay kit (Thermo Scientific, #23225). Immunoblotting analysis of His-tagged Her2-ED44 was carried out using a primary anti-tetra-His antibody (QIAGEN, #34670) and secondary anti-mouse-lgG-horse radish peroxidase conjugate (Sigma Aldrich, A4416). Endotoxin determination was carried out using the Endosafe®-PTS system (Charles River Laboratories, #PTS100) with Endosafe®PTS cartridges, sensitivity 10-0.1EU/ml (Charles River Laboratories, #PTS201).
- the frozen leaf powder (appr. 600 g to 1 kg) is mixed with approximately two volumes (w/v) of extraction buffer (200 mM sodium citrate, pH6, 5 mM EDTA) and incubated with shaking for about 40 minutes.
- extraction buffer 200 mM sodium citrate, pH6, 5 mM EDTA
- the homogenate is clarified by centrifugation at 15.000 x g for 10 minutes followed by filtration through MiraCloth filter.
- the extraction was repeated to ensure the maximal yield of expressed recombinant protein.
- the pH of the clarified homogenate is then lowered to pH 5.0 using sodium citrate solution for removal of host cell proteins including Rubisco.
- the pH of the crude extract is re-adjusted with 5 N NaOH to pH 7.4.
- the extract is centrifuged at 20.000 x g for 15 minutes to remove precipitates and cell debris and subsequently filtered through several membrane filters (20 ⁇ m - 8 ⁇ m - 3 ⁇ m and 0.45 ⁇ m) to obtain an extract suitable for subsequent column chromatography.
- the column material is equilibrated with 20 column (CV) volumes PBS pH7.34 prior loading the filtered protein extract. After loading, the column is washed with 20 CV wash buffer PBS, pH7.34. Column-bound protein is eluted with a low pH buffer (0.1 M Glycine pH2.9) via a peak-based fractionation and adjusted to a neutral pH with 0.4 M Na 2 HPO4.
- the eluate is further purified (polishing step) on a SartobindQ®SingleSep mini capsule, a strong basic anion exchanger (Sartorius, #92IEXQ42D4-SS).
- the SartoBinQ column was sanitized with 1 N NaOH, followed by equilibration with PBS pH5.0 before use.
- the pH of eluate was adjusted to 4.8 before loading into SartoBindQ column.
- the flow-though was collected and column was washed with PBS buffer (pH5.0) until base line UV280 nm is reached.
- the purified Her2-ED44-Kappa was concentrated using Spin-X UF concentrator 30k MWCO (Corning, #431489) and purified Tetanus Toxin Fragment C-Kappa was concentrated using Spin-X UF concentrator 50k MWCO (Corning, #431490). The concentrate was then sterile-filtrated using 0.2 ⁇ m filter. The concentration of purified protein is determined using BCA protein assay kit (Thermo Scientific, #23225). Endotoxin determination was carried out using the Endosafe®-PTS system (Charles River Laboratories, #PTS100) with Endosafe®PTS cartridges, sensitivity 10-0.1EU/ml (Charles River Laboratories, #PTS201).
- the frozen leaf powder is mixed with 3-5 volumes (w/v) of 0.1 M potassium phosphate buffer, pH7.0.
- the homogenate is incubated on ice on a shaker for approximately 30 minutes. Then, the homogenate is filtered through a MiraCloth filter into a prechilled tube. The filtrate is transferred into centrifuge tubes, 1 ⁇ 4 volume of chloroform is added and the solution is gently but thoroughly mixed for 20 minutes on ice. The mixture is centrifuged at 10,000 x g for 15 minutes at 4°C. The upper aqueous phase is transferred into a fresh centrifugation tube and 1/10 volume of 12% sodium chloride and 1/5 volume of 25% PEG-6000 is added.
- the mixture is incubated on ice for approximately 1 hour and centrifuged at 10,000 x g for 15 minutes at 4°C. The supernatant is carefully removed and 1/5 volume of 0.1 M potassium phosphate buffer, pH 7.0 is added. Finally, the mixture is incubated on ice until the pellet is dissolved. Quality of the viral particles is analyzed by SDS-PAGE. Approximately 12 mg purified TMV particles can be obtained from 6 g fresh leaf material.
- Her2-ED44-Kappa and Tetanus toxin Fragment C-Kappa or TMV viral particles are mixed (3 mg of each) for the conjugation reaction.
- Glutardialdehyde (25%) is added to the protein mixture to a final concentration of 0.1%.
- the mixture is incubated at room temperature for 2 hours and gently stirring.
- the reaction is stopped by addition of 2M glycine to a final concentration of 20 mM and incubation is continued for 30 minutes.
- the entire reaction is subjected to gel filtration for removal of remaining glutardialdehyde and non-conjugated proteins.
- the maximal volume of 2 ml of the reaction mixture was loaded onto a SuperdexTM 200 column (GE Healthcare, #17-1043-02) with a flow rate of 1 ml/min.
- the mobile phase is PBS buffer pH 7.34 and the flow through was collected in 10 fractions over the entire peaks areas.
- the conjugation efficiency is analyzed (15 ⁇ l of each fraction) by 8% SDS-PAGE under reducing conditions and immunoblot analysis using anti-human Kappa antibodies (Sigma Aldrich, #A7164). All conjugate containing fractions (molecular weight > 70 kDa) were pooled and concentrated using Spin-X UF concentrator 50k MWCO (Corning, #431490).
- Protein concentration of conjugate is determined using BCA protein assay kit (Thermo scientific #23225). Endotoxin determination was carried out using the Endosafe®-PTS system (Charles River Laboratories, #PTS100) with Endosafe®PTS cartridges, sensitivity 10-0.1EU/ml (Charles River Laboratories, #PTS201).
- mice BALB/c female mice aged between 6 and 10 weeks at the beginning of the procedures were kept in accordance with the Home Office Guidelines. Experiments were performed under Project Licence JR 70/6401 or AM 30/3028 and Personal Licence PIL 70/20084 (UoS). Mice are injected with 50 ⁇ g of Her2-ED44-His or conjugate vaccines containing an equivalent amount of Her2-ED44. Each mouse received either 50 ⁇ g of Her2-ED44, or 130 microgram of Her2-ED44-kappa-Fragment C-kappa, or 91 ⁇ g of Her2-ED44-kappa-TMV in 100 ⁇ L saline combined with an equal volume of alum adjuvant (Sigma).
- vaccines combined with alum were mixed end-over-end for 1h at ambient temperature.
- the injections are carried out subcutaneously into two sites in the flank. At least five mice per group were vaccinated per each experiment, except of Balb-NeuT where the group sizes were smaller.
- For the control vaccine 130 ⁇ g of plant expressed irrelevant protein (5T33Ig-hkappa-Fragment C fusion protein made by ICON) was given.
- a comparator vaccine, Her2/Neu-EC-TM DNA vaccine (50 ⁇ g) was injected intramuscularly into two site. Wild-type mice are injected twice with the same amount of vaccine, second injection was given three weeks after the first one ( Fig. 14 ).
- mice were bled 3 weeks after the first injection and two times after second injection with two weeks interval between the bleeds (week 5 and week 7).
- Balb-NeuT transgenic mice were vaccinated 5 times with the first injection given at 10 weeks of age with the subsequent injection given every three weeks. Blood samples were taken 2 weeks after each injection. The samples were analysed by ELISA for reactivity against Her2-ED44 and for reactivity against membrane bound Her2/neu as well as for IgG isotypes and affinity.
- mice were taken from vaccinated mice by tail bleeding.
- Local anesthetic (Instillagal®, FARCO-PHARMA GmbH, Cologne, Germany) was applied to the tip of the tails and mice were warmed at 37°C for 5 min.
- a 1-2 mm section of the tip of the tail was cut with a scalpel and up to 200 ⁇ L of blood was removed per mouse.
- whole blood was spun at 10,000 rpm for 10 minutes and the serum was collected. Serum samples were preserved by the addition of 1 mL of 1 mM sodium azide and store at -20°C.
- 96-well flat bottomed Nunc ImmunosTM ELISA plates (NUNC) were coated with Her2-ED44-His (3 ⁇ g/mL in carbonate/ bicarbonate buffer pH 9.6) overnight. The following day the plates were blocked with 1% BSA in PBS for 1 h at ambient temperature. Serial 4x dilutions of samples ranging from 1/100 to 1/6400 for week 3 samples and ranging from 1/1000 to 1/64000 for every subsequent time point were added to the plates and incubated for 1.5 h on a shaker at 37°C.
- TUBO cells are a cloned line derived from BALB/c mice which are transgenic for the transforming r-Her-2 / neu oncogene (BALB-NeuT) (Rovero, 2000) and used in the binding assay to assess the reactivity with the rat Her2/neu.
- TUBO cells were cultured in DMEM high glucose (PAA Laboratories) supplemented with penicillin-streptomycin and 20% FCS. When the cells reach 60-70% confluency they are incubated with TRYPSIN-EDTA(PAA Laboratories, Pasching, Austria) for 5-10 minutes at 37°C and then trypsin is stopped by split dilution. Splitting dilution can range from 1:3 to 1:6 or 1:8.
- the D2F2/E2 cells belong to a mammary tumor line from BALB/c mice which has been stably transfected with a vector expressing the human ERBB2 (Her2/neu) gene ( Piechocki, M.P., Pilon, S.A. & Wei, W.Z. 2001, J. Immunol., 167: 3367-3374 ).
- the D2F2/E2 cells were used in the binding assay to assess the reactivity with human Her2/neu.
- D2F2/E2 cell were cultured in high glucose DMEM supplemented with Penicillin-Streptomycin, 20% FCS and 800 ⁇ g/mL of G418 (Gibco). When confluent the cells were trypsinised and split by diluting between 1:4 and 1:8.
- single cell suspensions are prepared by passing the cells through a syringe after trypsinisation.
- Binding of the induced antibody was analyzed by FACS staining using previously published protocols with modifications (Rovero, 2000). Briefly, 2x10 5 (either Tubo or D2F2/E2) cells were initially pre-incubated with serum from naive mice to reduce nonspecific binding and then with 1/100 dilution of the immune sera derived from vaccinated mice. The staining was carried out in a total volume of 100 ⁇ L. Secondary anti-mouse F(ab')2 IgG labeled with eFluor660 (eBioscience# 50-4010-82, dilution 1/200), was used to detect the levels of induced antibody binding with a subsequent FACS analysis using FACS Callibur and Cell Quest software. The results of the measurements are shown in Figures 16-18 and 20 .
- the human HER2 positive breast cancer cell line BT474 was incubated separately with pooled sera from mice vaccinated at dilutions indicated, trastuzumab (Herceptin®, Roche, UK) or 30 ⁇ M of PI3K (downstream of Her2 signalling) inhibitor LY294002 (Cell Signalling Technology, Massachusetts, USA) for 1 hour. All treatments were carried out in complete DMEM media supplemented with 10% FCS at 37°C, 10% CO 2 .
- the cells were harvested, lysed and 10 ⁇ g of protein per sample were subjected to SDS-PAGE (NuPAGE® Novex® 4-12% Bis-Tris Gels, Invitrogen Life Technologies, California, USA) after denaturing at 95°C for 5 minutes.
- SDS-PAGE NuPAGE® Novex® 4-12% Bis-Tris Gels, Invitrogen Life Technologies, California, USA
- PVDF polyvinylidene difluoride
- the membranes were incubated with 1/1,000 in TBS-T of the HRP-conjugated secondary antibody (anti-rabbit IgG-HRP, Cell Signalling Technologies or anti-mouse IgG (Gamma)(AFF)-PEROX, The Binding Site, Birmingham, UK) for 1 hour at room temperature.
- the membrane was washed 3 times with TBS-T again before detection with the SuperSignalTM West Pico Chemiluminescent Substrate (Thermo Scientific, Illinois, USA).
- the chemiluminescent signal was captured using Bio-Rad imaging system (Fluor-S® Multilmager, Bio-Rad). The results of Western blotting are shown in Figure 19 .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (14)
- Anti-Krebsimpfstoff, umfassend ein Protein-Konjugat, das ein Protein-Antigen und einen immunogenen Träger umfasst, der kovalent an das Protein-Antigen gebunden ist, wobei das Protein-Antigen(i) ein Sequenzsegment von 300 oder mehr benachbarten Aminosäureresten der Aminosäuresequenz der SEQ ID Nr. 2 aufweist und höchstens 400 benachbarte Aminosäuren der Aminosäuresequenz der SEQ ID Nr. 1; oder(ii) eine Sequenzsegmentvariante von 300 oder mehr und höchstens 400 Aminosäureresten aufweist und von 1 bis 20 Substitutionen, Deletionen oder Additionen in der Sequenzsegmentvariante im Vergleich zu einem Sequenzsegment von 300 oder mehr Aminosäureresten der Aminosäuresequenz der SEQ ID Nr. 2 aufweist.
- Anti-Krebsimpfstoff nach Anspruch 1, wobei das Sequenzsegment des Protein-Antigens von 300 oder mehr benachbarten Aminosäureresten der Aminosäuresequenz der SEQ ID Nr. 1 das Aminosäure-Sequenzsegment von Aminosäure 332 bis 631 der SEQ ID Nr. 1 aufweist oder Sequenzsegmentvarianten wie in Punkt (ii) definiert.
- Anti-Krebsimpfstoff nach einem der Ansprüche 1 oder 2, wobei das Protein-Antigen oder das Protein-Konjugat kein weiteres Aminosäure-Sequenzsegment wie folgt enthält:ein weiteres Aminosäure-Sequenzsegment von 20 oder mehr, bevorzugt 10 oder mehr, benachbarten Aminosäureresten von einem Sequenzanteil der Aminosäuren 1 bis 253, bevorzugt 1 bis 283, noch von einem Sequenzanteil, der bei Aminosäure 670, bevorzugt bei Aminosäure 654 der SEQ ID Nr. 18 beginnt; oderein weiteres Aminosäure-Sequenzsegment von mehr als 20 benachbarten Aminosäureresten, das mehr als 50% Sequenzidentität mit dem Sequenzanteil der Aminosäure 1 bis 253, bevorzugt 1 bis 283 aufweist, noch zu einem Sequenzanteil, der bei Aminosäure 670, bevorzugt bei Aminosäure 654 der SEQ ID Nr. 18 beginnt.
- Anti-Krebsimpfstoff nach einem der Ansprüche 1 bis 3, wobei das Protein-Antigen, als weiteres Segment einen Reinigungs-Tag an dessen N- oder C-terminalen Ende, wie ein 6x-His-Tag oder eine konstante Region einer leichten Kette eines Antikörpers, umfasst und optional einen Linker, der das Reinigungs-Tag und das Sequenzsegment des Protein-Antigens verbindet.
- Anti-Krebsimpfstoff nach einem der Ansprüche 1 bis 4, wobei der immunogene Träger ein immunogenes Protein oder ein immunogenes Protein-Aggregat ist oder umfasst, wobei das immunogene Protein bevorzugt das Tetanus-Toxin-Fragment C oder das DOM1-Fragment desselben ist oder umfasst, oder das Protein-Aggregat ein Viruspartikel, wie ein pflanzlicher Viruspartikel, ist.
- Anti-Krebsimpfstoff nach einem der Ansprüche 1 bis 5, wobei das Protein-Antigen und der immunogene Träger kovalent durch eine chemische Vernetzung unter Verwendung eines chemischen Vernetzungsmittels gebunden werden.
- Anti-Krebsimpfstoff nach einem der Ansprüche 1 bis 6, wobei das Protein-Antigen aus einem ersten Sequenzsegment besteht, um eine Immunantwort gegen das HER2-Protein in einem Säugetier auszulösen und optional ein weiters Sequenzsegment, wobei das erste Sequenzsegment(i) eine Aminosäuresequenz von 300 oder mehr benachbarten Aminosäureresten der Aminosäure-Sequenz der SEQ ID Nr. 2 aufweist; oder(ii) eine Aminosäuresequenzvariante von 300 oder mehr Aminosäureresten aufweist und von 1 bis 20 Substitutionen, Deletionen oder Insertionen in der Sequenzvariante im Vergleich zu dem Sequenzsegment von 300 oder mehr Aminosäureresten der Aminosäuresequenz der SEQ ID Nr. 2 aufweist;wobei das Protein-Antigen oder das Protein-Konjugat kein weiteres Aminosäure-Sequenzsegment von 20 oder mehr, bevorzugt 10 oder mehr, benachbarten Aminosäuren von dem Sequenzanteil von Aminosäure 1 bis 253, bevorzugt 1 bis 283, noch von dem Sequenzanteil aufweist, der bei Aminosäure 670, bevorzugt bei Aminosäure 654 der SEQ ID Nr. 18 beginnt, und
wobei das Protein-Antigen und der immunogene Träger kovalent durch eine chemische Vernetzung unter Verwendung eines chemischen Vernetzungsmittels gebunden werden. - Protein-Antigen, bestehend aus einem ersten Aminosäure-Sequenzsegment mit einer Aminosäuresequenz, die Ähnlichkeit mit der des Her2/neu-Proteins aufweist, und optional einem oder mehreren weiteren Aminosäure-Sequenzsegmenten; wobei das erste Sequenzsegment(i) eine Aminosäuresequenz von 320 oder mehr benachbarten Aminosäureresten der Aminosäuresequenz der SEQ ID Nr. 2 und höchstens 370 benachbarte Aminosäurereste der Aminosäuresequenz der SEQ ID Nr. 1 aufweist; oder(ii) eine Aminosäuresequenzvariante von 320 oder mehr und höchstens 370 Aminosäureresten aufweist und von 1 bis 20 Substitutionen, Deletionen oder Additionen in der Sequenzvariante im Vergleich zu dem Sequenzsegment von 300 oder mehr Aminosäureresten der Aminosäuresequenz der SEQ ID Nr. 2 aufweist;und wobei jedes weitere Aminosäure-Sequenzsegment von 20 oder mehr, bevorzugt 10 oder mehr, benachbarten Aminosäureresten keinen Sequenzanteil von Aminosäure 1 bis 253, bevorzugt 1 bis 283, noch von einem Sequenzanteil aufweist, der bei Aminosäure 670, bevorzugt bei Aminosäure 654 der SEQ ID Nr. 18 beginnt; oder wobei jedes weitere Aminosäure-Sequenzsegment von mehr als 20 benachbarten Aminosäureresten nicht mehr als 50% Sequenzidentität mit dem Sequenzanteil von Aminosäure 1 bis Aminosäure 253, bevorzugt 1 bis 283 aufweist, noch zu einem Sequenzanteil, der bei Aminosäure 670, bevorzugt bei Aminosäure 654 der SEQ ID Nr. 18 beginnt.
- Eine Nukleinsäuresequenz, die für das Protein-Antigen nach Anspruch 8 codiert.
- Kit, umfassend das Protein-Antigen nach Anspruch 8 und ein immunogenes Protein oder Protein-Aggregat für die Vernetzung mit dem Protein-Antigen, um ein Protein-Konjugat zu bilden.
- Protein-Konjugat, umfassend das Protein-Antigen nach Anspruch 8 und einen immunogenen Träger, der kovalent an das Protein-Antigen gebunden ist.
- Anti-Krebsimpfstoff nach einem der Ansprüche 1 bis 7, ferner Wasser umfassend, in dem das Protein-Konjugat dispergiert ist, und optional ferner pharmazeutisch verträgliche Hilfsstoffe oder ferner ein immunologisches Hilfsmittel umfassend.
- Anti-Krebsimpfstoff nach einem der Ansprüche 1 bis 7 oder das Protein-Konjugat nach einem der Ansprüche 1 bis 7 oder das Protein-Antigen nach Anspruch 8, zur Verwendung in einem Verfahren zur Behandlung von HER2/Neu-positivem Krebs.
- Verfahren zur Herstellung des Protein-Konjugats nach Anspruch 11, umfassend das Bereitstellen eines Protein-Antigens oder der Variante und Vernetzen des Protein-Antigens oder der Variante mit dem immunogenen Träger.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14712205.5A EP2968489B1 (de) | 2013-03-11 | 2014-03-11 | Her2/neu-krebsimpfstoff |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13001211.5A EP2777711A1 (de) | 2013-03-11 | 2013-03-11 | HER2/neu-Krebsimpfstoff |
PCT/EP2014/000650 WO2014139672A1 (en) | 2013-03-11 | 2014-03-11 | Her2/neu cancer vaccine |
EP14712205.5A EP2968489B1 (de) | 2013-03-11 | 2014-03-11 | Her2/neu-krebsimpfstoff |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2968489A1 EP2968489A1 (de) | 2016-01-20 |
EP2968489B1 true EP2968489B1 (de) | 2018-08-08 |
Family
ID=47845698
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13001211.5A Withdrawn EP2777711A1 (de) | 2013-03-11 | 2013-03-11 | HER2/neu-Krebsimpfstoff |
EP14712205.5A Active EP2968489B1 (de) | 2013-03-11 | 2014-03-11 | Her2/neu-krebsimpfstoff |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13001211.5A Withdrawn EP2777711A1 (de) | 2013-03-11 | 2013-03-11 | HER2/neu-Krebsimpfstoff |
Country Status (6)
Country | Link |
---|---|
US (1) | US10052370B2 (de) |
EP (2) | EP2777711A1 (de) |
JP (2) | JP2016516678A (de) |
AU (1) | AU2014231214B2 (de) |
CA (1) | CA2905184A1 (de) |
WO (1) | WO2014139672A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102013015253A1 (de) * | 2013-09-13 | 2015-03-19 | Gleason-Pfauter Maschinenfabrik Gmbh | Meßgeometrie, Meßeinrichtung mit einer solchen Meßgeometrie und Meßverfahren |
US11998594B2 (en) | 2014-04-02 | 2024-06-04 | Case Western Reserve University | Anti-cancer plant virus particles linked to HER2 antigens |
US10098936B2 (en) * | 2014-04-02 | 2018-10-16 | Case Western Reserve University | Vaccination using plant virus particles linked to HER2 antigens |
MX2016013149A (es) * | 2014-04-10 | 2017-04-27 | Seattle Children's Hospital (Dba Seattle Children's Res Institute) | Produccion de celulas t modificadas, mediante transposon bella durmiente, acoplada con seleccion por metotrexato. |
CA2994829A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
EP3202783A1 (de) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Federale de Lausanne (EPFL) | Manipulierte antigen-präsentierende zellen und deren verwendung |
WO2019067673A1 (en) * | 2017-09-27 | 2019-04-04 | L2 Diagnostics, Llc | ERBB PEPTIDE-BASED PHARMACEUTICAL AND VACCINE COMPOSITIONS AND THEIR THERAPEUTIC USES FOR THE TREATMENT OF CANCER |
WO2019183600A1 (en) * | 2018-03-23 | 2019-09-26 | The Regents Of The University Of California | Methods and compounds for targeted autophagy |
US11696948B2 (en) | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
BR112020025250A2 (pt) | 2018-06-12 | 2021-03-09 | Kentucky Bioprocessing, Inc. | Purificação e conjugação de vírus e antígeno |
US11690907B2 (en) | 2018-06-12 | 2023-07-04 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
US11529413B2 (en) | 2018-06-12 | 2022-12-20 | Kbio Holdings Limited | Virus and antigen purification and conjugation |
CN109134656A (zh) * | 2018-09-12 | 2019-01-04 | 四川妙和生物科技有限公司 | 一种抗her2多克隆抗体 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4744984A (en) | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
CA2055441C (en) * | 1989-05-19 | 2003-01-07 | Robert M. Hudziak | Her2 extracellular domain |
US7820180B2 (en) * | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
US7198920B1 (en) * | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
ES2362715T3 (es) | 2000-03-30 | 2011-07-12 | Dendreon Corporation | Composiciones y métodos para inmunoterapia a base de células dendríticas. |
HU229642B1 (en) * | 2000-10-18 | 2014-03-28 | Glaxosmithkline Beecham Biolog S A | Vaccines against cancers |
ES2394293T3 (es) * | 2001-02-28 | 2013-01-30 | Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. | Vacuna contra cánceres que están asociados con el oncogén HER-2/neu |
WO2005049839A2 (en) | 2003-11-10 | 2005-06-02 | Icon Genetics Ag | Rna virus-derived plant expression system |
ITMI20041965A1 (it) | 2004-10-15 | 2005-01-15 | Augusto Amici | "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici" |
CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
EP1686176A1 (de) | 2005-01-28 | 2006-08-02 | Icon Genetics AG | Produktion von Antikörpern in Pflanzen mit plus-sense einzelsträngigen RNA Vektoren |
CN100398558C (zh) * | 2005-05-10 | 2008-07-02 | 中国人民解放军军事医学科学院基础医学研究所 | HER2/neu与Herstatin相互作用的活性片段及其编码基因与应用 |
EP1764414A1 (de) | 2005-09-17 | 2007-03-21 | Icon Genetics AG | Partikeln eines Pflanzenvirus, die eine Vielzahl von Fusionsproteinen bestehend aus einem Hüllprotein eines Pflanzenvirus, einem Peptidlinker und einem rekombinanten Protein umfassen, sowie deren Verwendung zur Proteinaufreinigung. |
EP2596801B1 (de) * | 2006-10-06 | 2018-05-02 | Bavarian Nordic A/S | Rekombinanter modifizierter vaccinia ankara-virus zur kodierung eines her-2-antigens zur verwendung in der krebsbehandlung |
AU2008223069B2 (en) | 2007-03-02 | 2012-12-13 | F. Hoffmann-La Roche Ag | Predicting response to a HER dimerisation inhibitor based on low HER3 expression |
PT2162149E (pt) | 2007-06-01 | 2014-02-12 | Jackson H M Found Military Med | Vacina para a prevenção da recaída do cancro da mama |
EP2292258A1 (de) * | 2009-08-18 | 2011-03-09 | Pevion Biotech Ltd. | Multiepitop-Impfstoff für Her2/neu-assoziierten Krebs |
CN102838679B (zh) * | 2011-06-23 | 2017-10-17 | 中国人民解放军第二军医大学 | Her2‑neu抗原阳性肿瘤治疗性疫苗的制备及应用 |
-
2013
- 2013-03-11 EP EP13001211.5A patent/EP2777711A1/de not_active Withdrawn
-
2014
- 2014-03-11 US US14/774,304 patent/US10052370B2/en active Active
- 2014-03-11 WO PCT/EP2014/000650 patent/WO2014139672A1/en active Application Filing
- 2014-03-11 JP JP2015561979A patent/JP2016516678A/ja active Pending
- 2014-03-11 CA CA2905184A patent/CA2905184A1/en active Pending
- 2014-03-11 EP EP14712205.5A patent/EP2968489B1/de active Active
- 2014-03-11 AU AU2014231214A patent/AU2014231214B2/en active Active
-
2020
- 2020-10-27 JP JP2020179595A patent/JP7102483B2/ja active Active
Non-Patent Citations (1)
Title |
---|
RESHMA SINGH ET AL: "In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 56, no. 6, 28 November 2006 (2006-11-28), pages 927 - 938, XP019514142, ISSN: 1432-0851, DOI: 10.1007/S00262-006-0237-4 * |
Also Published As
Publication number | Publication date |
---|---|
JP7102483B2 (ja) | 2022-07-19 |
AU2014231214A1 (en) | 2015-09-24 |
EP2968489A1 (de) | 2016-01-20 |
US20160015796A1 (en) | 2016-01-21 |
AU2014231214B2 (en) | 2018-01-18 |
WO2014139672A1 (en) | 2014-09-18 |
JP2016516678A (ja) | 2016-06-09 |
EP2777711A1 (de) | 2014-09-17 |
JP2021035375A (ja) | 2021-03-04 |
US10052370B2 (en) | 2018-08-21 |
CA2905184A1 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2968489B1 (de) | Her2/neu-krebsimpfstoff | |
Pinkhasov et al. | Recombinant plant‐expressed tumour‐associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1. Tg mice | |
Jones et al. | Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae Chlamydomonas reinhardtii | |
Klamp et al. | Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases | |
Obregon et al. | HIV‐1 p24–immunoglobulin fusion molecule: a new strategy for plant‐based protein production | |
McCormick et al. | Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig | |
US20190194680A1 (en) | Geminiviral vector for expression of rituximab | |
US8846052B2 (en) | Bacterial toxin vaccine | |
Beiss et al. | Heat‐precipitation allows the efficient purification of a functional plant‐derived malaria transmission‐blocking vaccine candidate fusion protein | |
Semenyuk et al. | Expression of single-chain antibody-barstar fusion in plants | |
Oh et al. | Co-transient expression of PSA-Fc and PAP-Fc fusion protein in plant as prostate cancer vaccine candidates and immune responses in mice | |
Matic et al. | The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2+ mammary cancer | |
CN113301918A (zh) | Cmv的通过融合修饰的病毒样颗粒 | |
KR20240111743A (ko) | Fc 단편 및 ab5 독소의 무독성 b 서브유닛을 포함하는 면역원성 융합 펩티드 | |
EP1315517A1 (de) | Mimetische peptiden für epitop von apolipoprotein b-100, concatemer und modifizierte peptide davon, und die impfstoffzusammensetzung mit solchen peptiden | |
US8912145B2 (en) | Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease | |
Rahdan et al. | Optimization of Expression and Purification of Recombinant Mouse plac1 | |
EP1263779B1 (de) | Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen | |
Jin et al. | Production, expression, and function of dual-specific monoclonal antibodies in a single plant | |
Sheikh et al. | Cloning, overexpression and characterization of soluble 42 kDa fragment of merozoite surface protein-1 of Plasmodium vivax | |
Thangaretnam et al. | Production and characterization of monoclonal antibodies against recombinant extracellular domain of CD99 | |
CA2405290C (en) | Vaccine against cancerous diseases | |
JP6999904B2 (ja) | マラリア伝播阻止型ワクチン | |
AU782856B2 (en) | Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules | |
JP2003116385A (ja) | 日本脳炎ワクチンをコードする遺伝子を含むトランスジェニック植物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150910 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20160721 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180118 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20180522 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1026227 Country of ref document: AT Kind code of ref document: T Effective date: 20180815 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014029911 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20180808 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1026227 Country of ref document: AT Kind code of ref document: T Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181109 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181108 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181108 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181208 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014029911 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20190509 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190311 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190311 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181208 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190311 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140311 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240327 Year of fee payment: 11 Ref country code: GB Payment date: 20240322 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240320 Year of fee payment: 11 |